Old gout drug could help hearts of people with type 1 diabetes
NCT ID NCT05949281
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a daily low dose of colchicine, an anti-inflammatory drug used for gout, can reduce inflammation and heart disease risk in adults with type 1 diabetes. 102 participants aged 35–80 will take either colchicine or a placebo for 26 weeks, with an optional 26-week extension and 5-year follow-up. The main goal is to see if colchicine lowers a key blood marker of inflammation (hsCRP).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
colchicine (0.5 mg oral tablet daily)
What this could lead to
If it works, this could point toward a way to lower heart disease risk in people with type 1 diabetes by reducing chronic inflammation.
What could go wrong
This is a small, early-phase trial testing only a marker of inflammation, not actual heart attacks or strokes. The drug may not show meaningful benefit or could cause side effects like stomach upset.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region, 2900, Denmark